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Unsaturated fatty acid regulation of cytochrome P450 expression via
a CAR-dependent pathway
Robert D. FINN, Colin J. HENDERSON, Claire L. SCOTT and C. Roland WOLF1
Cancer Research UK Molecular Pharmacology Unit, Biomedical Research Centre, Level 5, Ninewells Hospital and Medical School, Dundee DD1 9SY, U.K.
The liver is responsible for key metabolic functions, including
control of normal homoeostasis in response to diet and xenobiotic
metabolism/detoxification. We have shown previously that inac-
tivation of the hepatic cytochrome P450 system through condi-
tional deletion of POR (P450 oxidoreductase) induces hepatic ste-
atosis, liver growth and P450 expression. We have exploited a new
conditional model of POR deletion to investigate the mechanism
underlying these changes. We demonstrate that P450 induction,
liver growth and hepatic triacylglycerol (triglyceride) homoeo-
stasis are intimately linked and provide evidence that the
observed phenotypes result from hepatic accumulation of unsatu-
rated fatty acids, which mediate these phenotypes by activation of
the nuclear receptor CAR (constitutive androstane receptor) and,
to a lesser degree, PXR (pregnane X receptor). To our knowledge
this is the first direct evidence that P450s play a major role in
controlling unsaturated fatty acid homoeostasis via CAR. The
regulation of P450s involved in xenobiotic metabolism by this
mechanism has potentially significant implications for individual
responses to drugs and environmental chemicals.
Key words: constitutive androstane receptor (CAR), cytochrome
P450, linoleic acid, P450 oxidoreductase (POR), pregnane X
receptor (PXR), steatosis.
INTRODUCTION
Cytochrome P450 enzymes (P450s) play a major role in the meta-
bolism and disposition of chemicals and their activities are
critical in determining the efficacy or side effects of drugs.
These enzymes also have additional functions in adrenal steroid
hormone biosynthesis and the hepatic synthesis of cholesterol
and its degradation to bile acids [1]. The P450s involved in
these different pathways are distinct and their regulation has
conventionally been considered to be by different mechanisms.
This is manifest in that many of the hepatic enzymes involved
in foreign compound metabolism are expressed constitutively at
low levels, but become highly induced on exogenous chemical
exposure, resulting in an increased rate of excretion of the
compound(s). Significant advances have been made in our
understanding of this adaptive response through the identifica-
tion of transcription factors, such as AhR (aryl hydrocarbon
receptor), PXR (pregnane X receptor) and CAR (constitutive an-
drostane receptor), which have the capacity to bind drugs and exo-
genous chemicals, resulting in transcriptional activation of genes
that mediate their detoxification [2–5]. Although distinct classes
of compounds bind to each receptor, owing to the diversity of
these compounds’ chemical structures, promiscuity exists in their
specificity, particularly in the case of PXR and CAR [6,7].
We, and the group of Ding, have reported a mouse model where
hepatic P450 activity has been reduced by >95% by the condi-
tional deletion of the Por (P450 oxidoreductase) gene [8,9]. This
was achieved by crossing mice carrying the Por gene flanked
by loxP sites with mice expressing Cre recombinase under the
control of the rat albumin promoter. This resulted in the specific
hepatic deletion of POR neonatally with a concomitant reduc-
tion in P450 activity [8,9]. Although HRN (hepatic reductase-
null) mice developed normally and were fertile, there were a
number of intriguing phenotypic changes, including an enlarged
liver and hepatic steatosis. Also, there was a profound increase in
the expression of a range of P450s, with the most marked changes
being in the expression of CYP2B10 (CYP is cytochrome P450)
and CYP3A11 [10]. These enzymes, which are expressed at low
levels in untreated animals, are highly inducible by exogenous
chemicals such as barbiturates and synthetic glucocorticoids
[11,12]. These data show that the P450 system is a key regulator of
hepatic lipid homoeostasis and liver growth and that this metabolic
homoeostasis can have a profound effect on the control of P450
gene expression and, as a consequence, on the metabolism/
deposition of drugs. The HRN mouse therefore provides a model
for investigating the endogenous factors involved in regulating
P450 genes and the role of the P450 system in controlling hepatic
steatosis and liver growth.
Studies of the temporal events that lead to the hepatic phenotype
are, however, not possible in the HRN mice because the deletion of
the Por gene occurs neonatally. To overcome this, we have created
a model where the HRN genotype is regulated conditionally and
in an inducible manner. This was achieved by crossing Por-
floxed mice with mice where Cre recombinase is conditionally
regulated by the rat Cyp1a1 promoter. This promoter is activated
through the AhR, and administration of a single dose of 3MC
(3-methlycholanthrene) at 40 mg/kg results in a specific, time-
dependent, hepatic deletion of POR and a phenotype identical
with that observed in HRN mice [13].
In the present study, we have used the new model to study
the temporal biochemical changes that control lipid accumul-
ation and P450 overexpression. We provide evidence that dietary
unsaturated fatty acids play a key role in both lipid accumul-
ation and P450 induction. Also, using nuclear receptor/HRN
Abbreviations used: AhR, aryl hydrocarbon receptor; CAR, constitutive androstane receptor; Cpt1a, carnitine palmitoyltransferase 1a; CYP, cytochrome
P450; FAS, fatty acid synthase; HRN, hepatic reductase-null; i.p., intraperitoneal; 3MC, 3-methylcholanthrene; P450, cytochrome P450; PB, phenobarbital;
POR, P450 oxidoreductase; PPAR, peroxisome-proliferator-activated receptor; PUFA, polyunsaturated fatty acid; PXR, pregnane X receptor; TCPOBOP,
1,4-bis-[2-(3,5-dichloropyridyloxy)]benzene.
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44 R. D. Finn and others
double- and triple-knockout mice, we show that P450
overexpression occurs predominantly through the activation of
CAR.
EXPERIMENTAL
Reagents
All chemicals were purchased from Sigma–Aldrich, except where
indicated.
Production of transgenic mice
Porlox/lox/CreAlb (HRN) and Porlox/lox/CreCYP1A1 mice on a C57/BL6
genetic background were generated as described previously
[9,13]. Littermates with the Porlox/lox genotype were used as
controls. PXR-null (Pxr−/−) and CAR-null (Car−/−) mice on
a C57/BL6 genetic background were crossed on to the HRN
line to generate Pxr−/−/Porlox/loxCreAlb (Pxr−/−/HRN) and Car−/−/
Porlox/loxCreAlb (Car−/−/HRN) double-knockout mice respectively.
Pxr−/−/HRN and Car−/−/HRN were crossed to gener-
ate Car−/−/Pxr−/−/Porlox/loxCreAlb (Car−/−/Pxr−/−/HRN) triple-
knockout mice. Pxr−/−/Porlox/lox, Car−/−/Porlox/lox and Car−/−/
Pxr−/−/Porlox/lox littermates were used as controls. Pxr−/− and
Car−/− mice were identified by PCR as described previously
[14,15].
All mice were maintained under standard animal house condi-
tions with a 12 h light/12 h dark cycle and free access to water
and RM1 (control) diet (Special Diets Services). All studies were
carried out on 12-week-old male mice, except where indicated,
in accordance with the Animal Scientific Procedures Act (1986)
and after local ethical review.
Drug treatments
3MC in corn oil was administered to Porlox/lox/CreCYP1A1 and
Porlox/lox mice by i.p. (intraperitoneal) injection at 40 mg/kg of
body weight, and animals were killed at the indicated times.
Dietary restrictions
Porlox/lox/CreCYP1A1 and Porlox/lox mice were weaned and maintained
on a control diet until 8 weeks of age before being transferred
to either a fat-deficient diet (Special Diets Services, 821459)
or a fatty-acid-supplemented fat-deficient diet (Supplementary
Table S1 at http://www.BiochemJ.org/bj/417/bj4170043add.htm),
for an additional 6 weeks. As controls, both Porlox/lox/CreCYP1A1
and Porlox/lox mice were weaned and maintained on the control
diet for the duration of the experiment. All diets were isocaloric
and free from cholesterol. At 12 weeks of age, mice were
administered either a single i.p. dose of 3MC (40 mg/kg of body
weight) or corn oil, and killed 14 days later.
For linoleic acid treatment, Porlox/lox/CreCYP1A1 mice were main-
tained on the fat-deficient diet as described above. At 12 weeks of
age, mice were administered a single i.p. dose of 3MC (40 mg/kg
of body weight), followed by an oral dose of linoleic acid of
65 mg/day from day 5 after 3MC administration until being killed
9 days later.
Immunoblotting and biochemical analysis
Microsomal fractions were prepared by differential centrifugation
[12], and protein concentrations were determined using the Bio-
Rad Protein Assay Reagent. Western blot analysis was carried
out as described previously [16] using 5 μg of microsomal pro-
tein per lane and polyclonal antisera raised against human POR
[17], murine CYP7A1 [13] or rat P450s [16]. Purified human
POR, rat CYP4A1 and the following murine P450s, CYP2B10,
His6–CYP3A11 and His6–CYP7A1, were used as standards.
Immunoreactive proteins were detected using horseradish-
peroxidase-conjugated donkey anti-(rabbit IgG) as a secondary
antibody (Dako) and visualized by ECL® Plus (enhanced chemi-
luminescence (GE Healthcare). The relative protein content of
individual P450s in microsomal fractions was determined by
direct scanning of ECL® membranes with Bio-Rad Quantity One
densitometry software. POR activity was determined by NADPH-
dependent reduction of cytochrome c as described previously [17].
RNA isolation and real-time quantitative PCR analysis
Total RNA was isolated from snap-frozen liver samples using
TRIzol® (Invitrogen). Genomic DNA was removed using RQ1
DNase (Promega), and RNA (600 ng) was reverse-transcribed
using random hexamers and Superscript II RNase H reverse
transcriptase polymerase (Invitrogen). Real-time quantitative
PCR analysis was carried out with gene-specific primers for
CYP2B10, CYP3A11 and CAR as described previously [10]
and CD36 (Mm01135198_m1), FAS (fatty acid synthase)
(Mm01253292_m1) and Cpt1a (carnitine palmitoyltransferase
1a) (Mm00550438_m1) were supplied by Applied Biosystems.
Reactions were carried out in triplicate and monitored by meas-
uring fluorescence at 518 nm with excitation at 494 nm. mRNA
levels were quantified using the Prism 7700 associated software
and GAPDH (glyceraldehyde-3-phosphate dehydrogenase) as
an internal standard.
Blood chemistry
Blood was collected by cardiac puncture into heparinized tubes,
and plasma was analysed for non-fasting total cholesterol and non-
fasting triacylglycerols (triglycerides) using assay kits (Thermo
Trace) on a Cobas Fara II centrifugal analyser (Roche).
Histopathology
Tissue samples were snap-frozen in Cryo-M-Bed (Bright
Instrument Co.), cryo-sectioned (10 μm) and stained with Oil
Red O (lipid content) or haematoxylin and eosin (morphological
analysis).
Lipid isolation and analysis
A small piece of liver was homogenized in PBS containing 0.1%
Triton X-100, and hepatic triacylglycerol and cholesterol levels
were determined using assay kits on a Cobas Fara II centrifugal
analyser [18].
Detailed fatty acid analysis of the various diets was carried out
by Special Diet Services (Supplementary Tables S2 and S3 at
http://www.BiochemJ.org/bj/417/bj4170043add.htm).
Plasmid construction
The plasmids pCMX Gal4-hPXR-LBD and p4*4xGal4-UAS-
luciferase were a gift from Luisella Vignati (Department of
Pharmacokinetics, Dynamics and Metabolism, Gruppo Pfizer
Inc., Italy) [19] and the former was used as a source of
the pCMX Gal4 vector to facilitate the generation of further
reporter constructs. The mouse CAR ligand-binding domain from
amino acids 118–358 (mCAR-LBD) was amplified using 5′-GC-
GGAATTCGGTACTAAAGCATCTTTGCAACTGAA-3′ and 5′-
GCGGATCCTCAACTGCAAATCTCCCCGAGC-3′ as forward
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and reverse primers respectively, incorporating 5′ EcoRI and
3′ BamHI sites to facilitate cloning. The resulting 738 bp PCR
product was cloned as an EcoRI/BamHI fragment into pCMX
Gal4-hPXR-LBD replacing the hPXR-LDB section and generat-
ing the vector pCMX Gal4-mCAR-LBD.
Cell culture, transient transfection and cell treatments
All cell culture media and supplements were supplied by
Invitrogen. HepG2 cells were cultured in DMEM (Dulbecco’s
modified Eagle’s medium) containing 10% (v/v) heat-inactivated
foetal bovine serum, 1× non-essential amino acids, 100 units/ml
penicillin, 100 μg/ml streptomycin and 2 mM L-glutamine at
37 ◦C and 5% CO2.
HepG2 cells were transiently transfected with pCMX Gal4-
mCAR-LBD/p4*4xGal4-UAS-luciferase using the method of
Vignati et al. [19], with the following modifications: FuGENETM
6 (Roche) was used instead of LipofectamineTM Plus (Invitrogen),
assays were carried out in serum-containing medium and 0.2 μg
of the plasmid pRL-TK was included to allow normalization of
luciferase reporter gene activity. Cells were treated with
0.25–0.5 μM TCPOBOP {1,4-bis-[2-(3,5-dichloropyridyloxy)]-
benzene} and 1 mM PB (phenobarbital) as positive controls and
DMSO as a further control. Linoleic acid, complexed to fatty-
acid-free BSA at a molar ratio of 2:1, was tested at various
concentrations ranging from 0 to 12.5 μM, with the addition
of 20 μM α-tocopheryl succinate to prevent lipid peroxid-
ation. Luciferase reporter activity was determined using the Dual-
Luciferase Reporter Assay System (Promega).
RESULTS
Temporal analysis of the phenotypic changes observed
in the HRN mice
Porlox/lox/CreCYP1A1 mice, in the absence of a chemical inducer,
were phenotypically normal and indistinguishable from wild-type
animals. Treatment with a single dose of 3MC (40 mg/kg) led to a
time-dependent complete deletion of the hepatic POR and the dev-
elopment of a phenotype that was identical with that of the
original HRN model [13]. We therefore used this model to study
the sequential development of the HRN phenotypic traits over a
28 day period following 3MC treatment.
At 6 days after 3MC administration a >85% reduction in the
expression of POR protein, determined both by immunoblotting
and cytochrome c activity, had occurred (Figures 1A and 1B, i),
increasing to approx. 96% by day 14. These data were con-
firmed by immunohistochemistry where staining was reduced in
all hepatocytes by day 3 and undetectable on day 14 and remained
absent for at least 28 days (results not shown). Treatment with
3MC resulted in the anticipated induction of CYP1A1 as a
consequence of the activation of the AhR. By days 7–9, CYP1A1
levels, presumably due to the metabolism and elimination of 3MC,
were undetectable, indicating that the level of CYP1A1 was not
induced by the POR deletion (Figure 1A). The transient changes
observed in CYP1A1 expression imply that Cre recombinase
expression would follow the same pattern and suggest that
the deletion of POR is reversible. Cre recombinase is indeed
expressed transiently, similarly to CYP1A1; however, return
of POR is dependent on cell turnover, which, in the case of
hepatocytes, takes several weeks. In Porlox/lox/CreCYP1A1 mice, no
return of POR was observed for 60 days after 3MC treatment
(results not shown). In contrast, very marked increases in the
expression of other P450s were detected (Figure 1A). CYP2B,
CYP2C, CYP3A and CYP7A1 levels increased profoundly as a
function of time and in association with the decrease in POR
expression. Particularly marked changes were obtained in P450s
identified as CYP2B10 (corresponding to the upper band and
CYP2B9 to the lower band according to the findings of Li-Masters
and Morgan [20]) and CYP3A11. Interestingly, a stepwise
increase in the level of CYP2B proteins occurred between days 9
and 11, whereas the increase in CYP2C and CYP3A proteins ap-
peared to occur more gradually. An induction of CYP7A1
occurred on day 7 and continued to increase until day 21 (Fig-
ure 1A). CYP4A levels decreased from day 11 in both control
(Porlox/lox) as well as HRN mice, after which time they remained
slightly higher in HRN mice (results not shown). No changes
were observed in the expression levels of CYP2D proteins in
any samples. In control Porlox/lox animals, 3MC treatment had no
effect on any of the P450s measured other than on the induction
of CYP1A1 (results not shown).
Associated with the time-dependent reduction in POR were
changes in liver size and non-fasting plasma total cholesterol
and triacylglycerols levels (Figure 1B, ii, iii and iv). Significant
consistent changes in liver/body weight ratio were observed
from day 11, suggesting that other phenotypic changes must
precede this effect (Figure 1B, ii). A significant decrease in non-
fasting plasma triacylglycerol levels also occurred at this time
(Figure 1B, iv). A reduction in non-fasting total plasma cholesterol
levels was also observed which reduced steadily from day 3, in
parallel with POR reduction (Figure 1B, iii), indicating that the
reduction in triacylglycerols occurs independently of the changes
in cholesterol, but in parallel with liver enlargement.
Loss of POR also led to a profound increase in hepatic lipids
(Figure 1C). This accumulation occurred rapidly after 3MC
administration and paralleled the loss of POR. At early time
points, increases in lipid appeared to be localized to the perivenous
region, the major site of POR and P450 expression, and not to the
periportal region [21,22]. At later time points, this zonal local-
ization was lost, leading to lipid accumulation throughout the
liver. Quantification of hepatic lipid content demonstrated that
the hepatic steatosis was due to increases in hepatic triacylgly-
cerols by day 11 (Figure 2A). No significant changes in hepatic
cholesterol levels were observed over the entire time course of the
experiment (Figure 2B). The changes in hepatic triacylglycerol
content were closely correlated with changes in both liver/body
weight ratio and the reduction in plasma triacylglycerols
(Figures 2C and 2D). This suggests that the level of hepatic
triacylglycerols determines the circulating triacylglycerol levels
and that they are related to liver enlargement.
Changes in hepatic lipid homoeostasis mediate P450 induction
Hepatic deletion of POR led to a profound time-dependent induc-
tion of several P450s, including members of the CYP2B and
CYP3A families. This appeared to occur at both the protein and the
mRNA level [9,10]. Changes in CYP2B10 expression were first
seen on day 3, with a very marked increase between days 9 and 11
(Figure 1A). The increases in CYP2B10 protein and mRNA were
not correlated with the decrease in POR activity (Supplementary
Figure S1A, i and ii, at http://www.BiochemJ.org/bj/417/
bj4170043add.htm) and therefore did not appear to be due to
changes in the metabolism of an endogenous inducing agent.
However, CYP2B10 protein and mRNA levels were correlated
with each other, indicating that the induction of the Cyp2b10
gene occurs mainly at a transcriptional level (Supplementary Fig-
ure S1A, iii). In addition, Cyp2b10 mRNA levels were correlated
with hepatic triacylglycerol concentration (Supplementary Fig-
ure S1A, iv). Similar analysis for CYP3A11 indicated that the
increased protein expression occurred more rapidly than for
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Figure 1 Time course of the phenotypic changes in conditional HRN mice
Porlox /lox /CreCYP1A1 and Porlox /lox mice were treated with a single dose of 3MC (40 mg/kg of body weight) before plasma and liver samples were collected at the time points shown. (A) POR and P450
protein expression. Samples represent a pool of three animals per time point and 5 μg of hepatic microsomal protein per lane. Purified human POR and murine P450s were used as standards. (B) (i)
Hepatic microsomal POR activity. (ii) Liver/body weight ratios. Black bars: Porlox /lox /CreCYP1A1. Grey bars: Por lox /lox . (iii) Non-fasting plasma total cholesterol. (iv) Non-fasting plasma triacylglycerol
(triglyceride) levels. Results are means +− S.E.M. for three animals per time point, and in (i), (iii) and (iv) are expressed as a percentage compared with Porlox /lox mice at the same time point.∗P  0.05; ∗∗P  0.01; ∗∗∗P  0.001 compared with Porlox /lox mice. (C) Hepatic lipid content was visualized by Oil Red O staining of snap-frozen sections. Photomicrographs were taken at 10×
magnification, bright field, and are representative of the results from at least three mice per group.
CYP2B10, steadily increasing from day 2, reaching a maximum
by day 21, but also did not directly correlate with changes in
POR activity (Figure S1B). Although Cyp3a11 mRNA levels
were increased in POR mice, this did not correlate with the level
of CYP3A11 protein, indicating a more complex mechanism of
regulation of this gene (Supplementary Figure S1B, iii), possibly
involving both transcriptional and post-translational mechanisms.
Unlike Cyp2b10, only a weak correlation between the increases
in Cyp3a11 mRNA levels and hepatic triacylglycerol levels
was observed (Supplementary Figure S1B, iv). Thus differences
observed in the induction kinetics of CYP2B10 and CYP3A11,
at both the protein and the mRNA level, suggests that the
mechanisms regulating their overexpression are, at least in part,
distinguishable.
To determine the contributions of lipid uptake, oxidation and
synthesis to the development of the fatty liver phenotype and the
induction of P450s, changes in the expression levels of CD36, FAS
and Cpt1a were determined in 3MC-treated Porlox/lox/CreCYP1A1
mice compared with Porlox/lox mice (Supplementary Figure S2 at
http://www.BiochemJ.org/bj/417/bj4170043add.htm). No signi-
ficant changes in the expression levels of these genes were
observed, except for in Cpt1a on day 28 which showed a minor,
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Figure 2 Hepatic lipid accumulation and its relationship with organ weight and plasma lipid levels in conditional HRN mice
Porlox /lox /CreCYP1A1 and Porlox /lox mice were treated with a single dose of 3MC (40 mg/kg of body weight), and killed on the indicated days. (A) Hepatic triacylglycerol (triglyceride) concentrations. (B)
Hepatic cholesterol concentrations. Correlation of hepatic triacylglycerol concentration with (C) liver/body weight ratio and (D) non-fasting plasma triacylglycerol levels. Results are means +− S.E.M.
for three animals per time point. ∗P  0.05; ∗∗P  0.01 compared with lipid levels on day 1.
but significant, increase and may possibly be an attempt to
reverse lipid accumulation by increasing β-oxidation. Increased
expression of CD36 was observed on days 21 and 28 in
Porlox/lox/CreCYP1A1 mice, which may contribute to the increase
in hepatic lipid at these time points; however, no correlation
could be made before day 21. There was no correlation between
the expression levels of these genes and the increases in P450
expression. They therefore do not appear to contribute to the lipid
accumulation.
Dietary fatty acids mediate P450 induction in HRN mice
In view of the finding that changes in hepatic fatty acid
homoeostasis correlated with the increases in P450 expression,
detailed fatty acid analysis was carried out on livers from
HRN and Porlox/lox (control) mice (Supplementary Tables S4
and S5 at http://www.BiochemJ.org/bj/417/bj4170043add.htm).
Changes in all fatty acid classes occurred; however, the
most significant changes were in mono-unsaturated and
polyunsaturated fatty acids (Supplementary Table S5), with
C16:1, C18:1 and C20:3 increasing 6.78-, 14.06- and 6.19-fold
respectively (Supplementary Table S4). These data are in close
agreement with the report of Weng et al. [23], who, for their
HRN model, reported additional fold changes of 7.3 and 14.9 for
C18:3 and C20:1 unsaturated fatty acids respectively. Together, these
findings suggest that the accumulated hepatic triacylglycerols
preferentially contain unsaturated fatty acid chains and that these
fatty acid classes may mediate the P450 induction.
In the light of this possibility, Porlox/lox/CreCYP1A1 mice were
placed on a fat-deficient diet for 4 weeks before 3MC administr-
ation. This treatment completely prevented the increases in
P450 protein and mRNA expression as a consequence of POR
deletion (Figure 3A). Maintenance of control Porlox/lox mice on
a fat-deficient diet caused slight reductions in the constitutive
expression of CYP7A and CYP2C protein, and did not affect the
levels of the other P450s (results not shown). In addition to
the changes in hepatic P450 expression, maintenance of Porlox/lox/
CreCYP1A1 mice on a fat-deficient diet prevented the accumulation
of lipid in the livers of these animals (Figure 3C), resulting in an
Oil Red O staining pattern that was indistinguishable from that
of Porlox/lox mice on a control diet. Also no significant changes in
total plasma cholesterol or triacylglycerol levels were measured
on deletion of POR in Porlox/lox/CreCYP1A1 mice fed a fat-deficient
diet (Supplementary Figure S3). These data indicate that hepatic
triacylglycerol accumulation in POR mice originates from the
diet and that as a consequence of the inactivation of the P450
system an inability to maintain hepatic lipid homoeostasis occurs
which triggers increased P450 expression (possibly in an attempt
to restore normal hepatic lipid levels). It is worth noting that the
fat-deficient diet also prevented the liver enlargement seen on POR
deletion, thus providing a metabolic link to all three phenomena.
In order to identify the fatty acids that mediated P450 induction,
various fatty acids were added back to the fat-deficient diet
as outlined in Supplementary Table S1. Porlox/lox/CreCYP1A1 and
Porlox/lox were maintained on the supplemented diets and analysed
14 days after 3MC administration. In diets containing unsaturated
fatty acids, the loss of P450 gene expression observed with the fat-
deficient diet was reversed. This was particularly the case for diets
containing sunflower oil (which is composed of approx. 88%
unsaturated fatty acids) (Figure 3B, Supplementary Table S2). The
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Figure 3 Development of phenotypic changes in conditional HRN mice on
restricted fatty acid diets
Porlox /lox /CreCYP1A1 mice were maintained on a control diet until 8 weeks of age, and then
either placed on a fat-deficient or fatty-acid-supplemented diet, or continued on the control
diet, for a further 6 weeks. At 12 weeks of age, they were treated with a single dose of 3MC
(40 mg/kg of body weight) and killed 14 days later. (A) POR and P450 expression levels in
Porlox /lox /CreCYP1A1 and Porlox /lox mice maintained on a control or fat-deficient diet treated
with 3MC (+) or corn oil (CO) (−). (i) Protein expression determined by Western blotting.
Hepatic Cyp2b10 (ii) and Cyp3a11 (iii) mRNA levels expressed as a fold change compared with
Porlox /lox mice. (B) POR and P450 expression levels in Porlox /lox /CreCYP1A1 mice maintained
on fatty-acid-supplemented diets and treated with 3MC. (i) Protein expression determined by
Western blotting. Hepatic Cyp2b10 (ii) and Cyp3a11 (iii) mRNA levels expressed as a fold change
compared with Porlox /lox mice. (C) Hepatic lipid content determined by Oil Red O staining of
snap-frozen liver sections of Porlox /lox /CreCYP1A1 mice maintained on fatty-acid-supplemented
diets and treated with 3MC. Photomicrographs were taken at 10× magnification, bright field, and
are representative of the results from at least three mice per group. For mRNA analysis in (A)
and (B), results are means +− S.E.M. (n = 3). ∗P  0.05; ∗∗P  0.01; ∗∗∗P  0.001 compared
with Porlox /lox mice. std, standard. Black bars: Porlox /lox /CreCYP1A1; grey bars: Por lox /lox . In all
panels: SFA, saturated fatty acids; MUFA, mono-unsaturated fatty acids; PUFA, polyunsaturated
fatty acids; SunFl, 1 % sunflower oil.
inclusion of saturated fatty acids in the diet was essentially without
effect. None of the treatments had effects on POR or P450 gene
expression in the control Porlox/lox animals, with the exception of
CYP4A which was induced by all three unsaturated fatty acid diets
(results not shown). Analysis of Cyp2b10 and Cyp3a11 mRNA
levels confirmed that the changes in protein expression were at
least in part a result of transcriptional activation, the highest
increases in mRNA being found in mice on the sunflower-oil-
supplemented diet (Figure 3B, ii and iii). Analysis of plasma lipid
levels revealed some minor decreases in both total cholesterol and
triacylglycerol levels between Porlox/lox/CreCYP1A1 and Porlox/lox for
all dietary treatments; however, these were only significant for the
sunflower-oil-supplemented diet where a 1.5- (P = 0.036) and
1.8- (P = 0.013) fold decrease was observed respectively (Sup-
plementary Figures S3A and S3B at http://www.BiochemJ.org/
bj/417/bj4170043add.htm). Hepatic lipid accumulation was
observed for all diets, except for the fat-deficient diet, indicating
that lipid accumulation alone is not sufficient to cause P450
induction (Figure 3C). In addition, no significant increases in
liver/body weight ratio were observed for the diets used, except
that containing sunflower oils (Supplementary Figure S3C). These
data indicate that lipid accumulation alone was not the cause of
liver enlargement, but that unsaturated fatty acids had the capacity
to induce the effect. Comparison of the fatty acid composition
of the diets (Supplementary Tables S2 and S3), identified C18:2
(linoleic acid), an n − 6 PUFA (polyunsaturated fatty acid), as a
candidate fatty acid mediator of both P450 induction and liver
growth as it was the only fatty acid present in the diets that cor-
related with the effects observed. This hypothesis suggests that
the addition of linoleic acid as the sole dietary fatty acid should
be sufficient to induce P450 expression in Porlox/lox/CreCYP1A1 mice
maintained on a fat-deficient diet. This was indeed found to be
the case, with oral administration of linoleic acid (65 mg/day
for 9 days) to Porlox/lox/CreCYP1A1 mice on a fat-deficient diet,
resulting in induction of CYP2B10, CYP3A11 and CYP2C
proteins (Figure 4A). Analysis of Cyp2b10 and Cyp3a11 mRNA
levels showed this induction to occur at the transcription level
(Figure 4B). In addition, administration of linoleic acid was
found to promote hepatic lipid accumulation (Figure 4C). This
lipid accumulation was reduced compared with Porlox/lox/CreCYP1A1
mice maintained on a control diet and appeared to be concentrated
around the blood vessels, a pattern similar to that observed at early
time points following 3MC administration (Figure 1C); however,
in this case, it is probably due to differences in the amount of fat
intake. These results therefore indicate that linoleic acid, an n − 6
dietary essential fatty acid, is a key regulator of P450 expression
in HRN models and that members of the CYP2B, CYP3A and
CYP2C, in a normal physiological situation, are involved in its
metabolism.
Role of nuclear receptors in P450 induction in HRN mice
Nuclear receptors that have been shown to mediate the regulation
of many P450 genes in response to exogenous chemicals [24,25]
have also been shown to play an important role in controlling
liver growth [26,27]. Of particular interest with regards to this
study were CAR and PXR, which have been intimately linked
to the regulation of CYP2B and CYP3A proteins in response to
both exogenous and endogenous inducing agents [28–30], and
PXR has been linked to triacylglycerol homoeostasis [27]. In
order to investigate whether these nuclear receptors mediate the
P450 overexpression in the HRN mice, we crossed the HRN
animals with mice nulled at either the Car or Pxr locus alone
or in combination to generate Car−/−/HRN, Pxr−/−/HRN and
Pxr−/−/Car−/−/HRN genotypes.
c© The Authors Journal compilation c© 2009 Biochemical Society© 2008 The Author(s)
The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/)
which permits unrestricted non-commerical use, distribution and reproduction in any medium, provided the original work is properly cited.
9
ci
CAR-dependent fatty acid regulation of cytochromes P450 49
Figure 4 Induction of hepatic P450 expression in conditional HRN mice by linoleic acid
Porlox /lox /CreCYP1A1 mice were maintained on a control diet until 8 weeks of age, and then placed on a fat-deficient diet for a further 6 weeks. At 12 weeks of age, they were treated with a
single dose of 3MC (40 mg/kg of body weight) and 5 days later administered linoleic acid (65 mg/day) for 9 days before being killed. (A) POR and P450 expression levels were determined by
Western blotting. WT, wild-type; std, standard; Con, control; F.D., fat-deficient diet. (B) Hepatic Cyp2b10 (black bars) and Cyp3a11 (grey bars) mRNA levels expressed as a fold change compared
with Porlox /lox /CreCYP1A1 mice maintained on a fat-deficient diet. Results are means +− S.E.M. (n = 3). ∗P  0.05 compared with Porlox /lox /CreCYP1A1 mice maintained on a fat-deficient diet.
(C) Hepatic lipid content determined by Oil Red O staining of snap-frozen liver sections. Photomicrographs were taken at 10× magnification, bright field, and are representative of the results from at
least three mice per group.
Loss of PXR did not affect POR deletion or the induction of
P450 proteins observed in HRN mice (Figure 5A). In agreement
with previous findings, Pxr−/− mice exhibited slight increases in
CYP3A11 protein [14], and also CYP2B and CYP2C proteins
(Figure 5A, i); Cyp3a11 mRNA was also elevated relative to
levels in control Porlox/lox mice (Figure 5A, ii). Basal expression
of Cyp2b10 mRNA was also very slightly increased (Figure 5A,
ii), although this was not reflected in detectable protein expression
(Figure 5A, i). The deletion of PXR did not affect the increases in
both CYP2B10 and CYP3A11 protein in HRN animals; however,
a reduction in both Cyp2b10 and Cyp3a11 mRNA levels was
observed, but this was not significant compared with HRN mice
(Figure 5A, ii). No changes in plasma and hepatic lipid levels
were observed in Pxr−/−/HRN mice compared with HRN mice
(Supplementary Table S6 at http://www.BiochemJ.org/bj/417/
bj4170043add.htm and Figure 5D); however, in Pxr−/− mice, non-
fasting plasma total cholesterol and triacylglycerol levels were
reduced, the former significantly, in comparison with wild-type
mice (Supplementary Table S6).
In relation to HRN mice nulled for CAR, profound changes
in the HRN phenotype were observed. The elevated expression
of CYP2B, CYP7A and CYP2C was markedly attenuated; how-
ever, CYP3A11 expression appeared to be unaffected (Figure 5B).
Analysis of mRNA levels also showed that no induction of
Cyp2b10 mRNA occurred in Car−/−/HRN mice, indicating that
the increase in the expression of this P450 observed in HRN
mice was a consequence of CAR activation (Figure 5B, ii).
Interestingly, deletion of CAR in both control and HRN mice
further increased Cyp3a11 mRNA levels (Figure 5B, ii). The
reduction in non-fasting plasma total cholesterol and triacyl-
glycerol levels observed in the HRN mice were, however, not
reversed on the Car−/− background (Supplementary Table S6);
however, a significant reduction in hepatic lipid content for
Car−/−/HRN mice compared with HRN mice was observed
(Figure 5D). These data suggest that, in addition to mediating
P450 induction in HRN mice, CAR plays a role in hepatic lipid
accumulation.
Finally, owing to the cross-talk between PXR and CAR [31], the
effect of deleting both receptors on the development of the HRN
phenotype was analysed. In Pxr−/−/Car−/−/HRN mice, consistent
with the Car−/− mice, the expression of CYP2B and CYP2C
proteins was profoundly reduced, whereas, in contrast, CYP7A
expression levels were only slightly affected (Figure 5C). In mice
nulled at both the Car and Pxr gene loci, a marked decrease in
CYP3A11 protein was also observed (Figure 5C, i). The change
in CYP2B protein expression was also reflected in a reduction in
Cyp2b10 mRNA levels (Figure 5C, ii). A slight decrease
in Cyp3a11 mRNA was observed in Pxr−/−/ Car−/−/HRN mice,
although this was not significantly different from that of HRN or
Pxr−/−/Car−/− mice (Figure 5C, ii). Deletion of both CAR and
PXR on an HRN background resulted in an increase in non-fasting
plasma total cholesterol level that was not significantly different
from control (Porlox/lox) mice. Although an increase in plasma
triacylglycerols was also observed, this was not significantly
different from the HRN value (Supplementary Table S6). Hepatic
lipid content was reduced in Pxr−/−/Car−/−/HRN mice compared
with HRN mice, similar to levels observed in Car−/−/HRN mice,
but still elevated compared with controls (Figure 5D); however,
this reduction did result in a change in liver size (Supplementary
Table S6).
Direct activation of CAR by linoleic acid in HRN mice
In order to establish whether PUFAs could activate CAR directly,
we carried out transactivation assays using a Gal4-CAR-LBD
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Figure 5 Induction of hepatic P450 expression and other phenotypes in HRN mice on nuclear receptor-null backgrounds
(A) POR and P450 expression levels in Pxr−/−/HRN mice: (i) protein expression determined by Western blotting; and (ii) hepatic Cyp2b10 (black bars) and Cyp3a11 (grey bars) mRNA levels
expressed as a fold change compared with Porlox /lox mice. (B) POR and P450 expression levels in Car−/−/HRN mice: (i) protein expression determined by Western blotting; and (ii) hepatic Cyp2b10
(black bars) and Cyp3a11 (grey bars) mRNA expressed as a fold change compared with Porlox /lox mice. (C) POR and P450 expression levels in Car−/−/Pxr−/−/HRN mice: (i) protein expression
determined by Western blotting; and (ii) hepatic Cyp2b10 (black bars) and Cyp3a11 (grey bars) mRNA expressed as a fold change compared with Porlox /lox mice. (D) Hepatic lipid content determined
by Oil Red O staining of snap-frozen liver sections. Photomicrographs were taken at 10× magnification, bright field, and are representative of the results from at least three mice per group. For mRNA
analysis in (A), (B) and (C), results are means +− S.E.M. (n = 3). ∗P  0.05; ∗∗P  0.01; ∗∗∗P  0.001 compared with Porlox /lox mice. WT, wild-type.
reporter assay in HepG2 cells [32]. In these experiments,
both TCPOBOP and linoleic acid could activate CAR directly
(Figure 6). PB, which is known to activate CAR by an indirect
mechanism, was not active in this assay. In view of reports that
the fatty-acid-sensitive transcription factor, PPARα (peroxisome-
proliferator-activated receptor α) can effect CAR expression
[33,34] and that the effects in the POR mice may be indirect,
we measured Car mRNA expression in Porlox/lox/CreCYP1A1 mice.
Expression levels of CAR were found to be unchanged (Supple-
mentary Figure S2D).
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Figure 6 Activation of CAR by linoleic acid
HepG2 cells were transfected with pCMX Gal4-mCAR-LBD and p4∗4xGal4-UAS4-luciferase as
outlined in the Experimental section. Transfected cells were subsequently treated with linoleic
acid at a concentration ranging from 0 to 12.5 μM, and luciferase activity was analysed 24 h later.
Transfected cells were treated with 0.25–0.5 μM TCPOBOP or 1 mM PB as positive and negative
controls respectively. Results are means +− S.E.M. (n = 6 determinations) and are expressed as
a fold change compared with cells treated with either DMSO in the case of TCPOBOP and PB or
the 0 μM sample in the case of linoleic acid. ∗P  0.05; ∗∗∗P  0.001.
DISCUSSION
The liver is the major organ controlling metabolic homoeostasis
due to dietary change. It is also the major tissue responsible for
drug and dietary chemical detoxification through the actions of
phase I and phase II drug metabolism in which the P450 system
plays a pivotal role. Although it has been known for some time
that alterations in diet and disease states such as diabetes affect
the P450 system, there has been little evidence that P450s can
play a direct role in metabolic control [35–37]. However, there is
a growing body of evidence, as demonstrated in the present paper,
that these pathways are intimately linked. This has a wide range
of implications not only for how alterations in P450 function may
influence the pathogenesis of disease, but also for how diet and
disease states may influence the metabolism and disposition of
drugs and environmental agents; for example, obesity in rats has
been shown to reduce expression levels of CAR and impaired
CYP2B induction by PB [38].
The metabolic dialogue between the pathways of detoxification
and metabolic homoeostasis are manifest in the findings that,
when the P450 system is inactivated, profound changes in lipid
homoeostasis and liver size occur which are paralleled by the
marked induction of P450s associated with drug metabolism in
the absence of an exogenous inducing agent. We have demon-
strated that P450s from a range of gene families are induced and
that this induction parallels the accumulation of hepatic triacylgly-
cerols. We have also shown that the regulation of different P450s
is, in part, distinguishable, as exemplified by CYP2B10 and
CYP3A11. CYP2B10 induction is almost entirely controlled at
the transcriptional level and occurs at a time point when there is
a stepwise increase in triacylglycerol accumulation, whereas, in
the case of CYP3A11, there is only a poor correlation between
mRNA induction and protein levels, indicating that both transcrip-
tional and post-translational mechanisms are involved. The
latter mechanism could possibly occur via phosphorylation or
ubiquitination [39–41]. This may also be the case for CYP2C
proteins. Evidence for distinct pathways of regulation is also
reflected in the finding that the overexpression of these proteins
is, at least in part, mediated by different transcription factors (see
below). We have also demonstrated that hepatic steatosis is not
sufficient to induce the hepatic P450 expression, but this effect
is mediated by dietary unsaturated fatty acids such as linoleic
acid, which we have found is sufficient on its own to reverse the
fat-deficient phenotype.
P450s of the CYP2B family are the major enzymes induced
in the liver by barbiturate drugs such as PB [42] and have the
capacity to metabolize fatty acids such as arachidonic acid [43].
Interestingly, Fulco and co-workers demonstrated over 20 years
ago that a fatty acid mono-oxygenase involved in fatty acid oxid-
ation in Bacillus megaterium is highly inducible by PB [44,45]. In
fact, studies on this pathway have demonstrated that its induction
provides an adaptive response against unsaturated fatty acid
toxicity [46]. Whether the induction of enzymes such as CYP2B10
and CYP3A11 in mammals are part of a similar detoxification
pathway against dietary unsaturated fatty acids which are not
produced endogenously, such as linoleic acid, remains to be deter-
mined. However the data in the present study do raise the possibil-
ity that, under certain circumstances, diets containing unsaturated
fatty acids may influence hepatic detoxification systems.
A wide range of transcription factors have now been discovered
which control fatty acid homoeostasis and liver growth, including
PPARα, CAR, PXR, LXR (liver X receptor) and HNF4α (hepato-
cyte nuclear factor 4α) [26,27,47–49]. For example, it has been
demonstrated that PPARα mediates liver growth induced by
perturbations in fatty acid homoeostasis as a consequence of
peroxisome proliferation and that PXR plays a role in controll-
ing hepatic triacylglycerol homoeostasis [27,50,51]. It was
therefore intriguing that the majority of the phenotypes resulting
from inactivation of the hepatic P450 system and the downstream
effects on fatty acid homoeostasis were mediated by the transcrip-
tion factor CAR. It has been postulated for some time that CAR
function is regulated by both endogenous and exogenous inducing
agents including metabolic control through AMPK (AMP-activ-
ated protein kinase) [52], interaction with the forkhead transcrip-
tion factor FoxO1 (forkhead box O1) [53] and activation during
fasting [54]. It has also been postulated that CAR function can be
modulated by the fatty-acid-sensitive transcription factor PPARα
[33,34]. However, this mechanism of CAR activation would not
appear to explain the hepatic phenotype, as no changes in CAR
expression were found and also linoleic acid activated CAR dir-
ectly. However, to our knowledge, the finding that CAR may play
a role in linking the control of hepatic lipid homoeostasis and
endogenous P450 expression has not been reported previously.
We provide additional evidence that, for one group of enzymes
in the Cyp3a gene family, PXR may also play a role in defining
the response to unsaturated fatty acids. The finding that feeding
conditional HRN mice a fat-deficient diet prevents the induction
of CYP3A11 suggests that fatty acids, as well as bile acids [14],
can influence PXR function.
A possible pathway linking P450 function to the findings
observed in the present study is shown in Figure 7. As described in
this model, dietary unsaturated fatty acids enter the liver via fatty
acid transporters, where, in wild-type mice, they are oxidized for
energy purposes or detoxified by P450s. Inactivation of the P450
system as a result of Por deletion leads to hepatic accumulation
of unsaturated fatty acids initially via increase import due to the
induction of lipid transporters such as CD36 [23] and a reduction
of plasma lipid levels. Hepatic lipid accumulation triggers the
activation of the nuclear receptor CAR (and possibly PXR),
leading to P450 induction and liver growth through the activation
of other downstream growth/transcription factors [26,27]. The
overexpression of P450s is aimed at re-establishing hepatic
lipid homoeostasis and the prevention of toxicity via increased
metabolism of unsaturated fatty acids. Inactivation of POR
prevents this increased metabolism and ultimately leads to hepatic
steatosis, which establishes a cyclical process that promotes fur-
ther hepatic lipid accumulation and growth. The ability to control
the hepatic deletion of POR conditionally using the CYP1A1–
Cre system has allowed us to provide evidence in support of
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Figure 7 Schematic representation of the phenotypic changes that occur in HRN mouse models
Dietary unsaturated fatty acids enter the liver via fatty acid transporters where they are oxidized for energy purposes or detoxified by P450s. Inactivation of the P450 system as a result of Por deletion
leads to hepatic accumulation of unsaturated fatty acids and a reduction of plasma lipid levels. Hepatic lipid accumulation triggers the activation of the nuclear receptor CAR (and possibly PXR),
leading to P450 induction and liver growth. The overexpression of P450s is aimed at re-establishing hepatic lipid homoeostasis and the prevention of toxicity via increased metabolism of unsaturated
fatty acids. Inactivation of POR prevents this increased metabolism and ultimately leads to hepatic steatosis. The development of steatosis establishes a cyclical process that potentiates hepatic lipid
accumulation and growth. The adverse effect of P450 induction is altered drug metabolism and environmental chemical detoxification, but, in addition, the increased production of oxidized lipids
could result in development of oxidative stress.
this pathway. Activation of Cre through the administration of
3MC resulted in the rapid deletion of POR, in that over 85%
of hepatocytes did not express the protein after 6 days. Although
accumulation of lipid was already occurring at this time point,
there appears to be a threshold at which point the CAR pathway
becomes activated. This hypothesis is supported by the finding that
it was only after 9–11 days that a marked change in triacylglycerol
accumulation occurred which was linked directly to changes in
plasma lipids, liver growth and P450 induction. Loss of P450
activity itself was not responsible for its auto-induction (although
the corresponding accumulation of a metabolite produced, e.g.
a bile acid precursor, which binds to CYP3A11 could explain
the stabilization of this protein). Whether the inactivation of the
P450 system causes the triacylglycerol accumulation and liver
growth and whether their induction is to attenuate the phenotypic
changes produced remains uncertain; however, it is quite clear that
the accumulation of hepatic triacylglycerols activates CAR. The
demonstration of cross-talk between drugs and lipids on CAR im-
plies that there will be drug–lipid interactions associated with ef-
fects on this receptor and evidence for this is provided by the work
of Li et al. [55], who showed that PUFAs could influence the
induction of P450 genes by PB. Why the HRN phenotype results
in the reduction in circulating triacylglycerols and cholesterol
remains to be established. It is interesting to note, however, that
the cholesterol 7α-hydroxylase enzyme (CYP7A1) involved in
bile acid homoeostasis also appears to be affected by unsaturated
fatty acid levels in a CAR-dependent manner and possibly a PXR-
dependent manner, as suggested by the opposing effects on this
protein’s expression observed in Car−/− and Pxr−/−/Car−/−/HRN
mice. The effect observed here on this enzyme’s expression is
intriguing as a previous report suggested that CAR activation
represses CYP7A1 expression [56]. The contrasting results may
be a consequence of the fact that fasted, as opposed to non-fasted,
animals were used in the study of Miao et al. [56]. Despite this,
these data suggest the existence of a new pathway for the dietary
regulation of CYP7A1 by unsaturated fatty acids.
In summary, we have used a novel conditional HRN model to
investigate the sequential development of the phenotypic changes
observed in mice on deletion of POR. POR deletion and the
associated inactivation of hepatic P450 function leads to accumul-
ation of dietary fatty acids in the liver, in the form of triacyl-
glycerols of unsaturated fatty acids, leading to organ enlarge-
ment and increased P450 expression, in the case of CYP2B,
CYP2C and CYP7A1 via a CAR-dependent signalling pathway.
The molecular mechanism underlying CYP3A11 expression
appears to involve CAR, PXR and protein stabilization. Induction
of the P450 system appears to be mediated by the accumulation of
PUFAs, such as linoleic acid (C18:2,n−6) and suggests that this may
be part of an adaptive response to prevent the deleterious effects
of PUFA accumulation. The finding that the major P450s that are
inducible by exogenous chemicals are also regulated by changes
in fatty acid homoeostasis has potentially significant implications
for the variability observed in drug responses in humans.
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Unsaturated fatty acid regulation of cytochrome P450 expression via a
CAR-dependent pathway
Robert D. FINN, Colin J. HENDERSON, Claire L. SCOTT and C. Roland WOLF1
Cancer Research UK Molecular Pharmacology Unit, Biomedical Research Centre, Level 5, Ninewells Hospital and Medical School, Dundee DD1 9SY, U.K.
EXPERIMENTAL
Lipid isolation and analysis
For detailed fatty acid analysis, livers from 12-week-old HRN
male mice were collected and lipid-extracted using a modified
version of the Folch method [1]. Briefly, internal standard
triheptadecanoin was added to a weighed amount of wet mouse
liver and homogenized in chloroform/methanol (1:1, v/v). An
equal volume of saline was added, before being centrifuged, and
the organic layer was removed and dried under vacuum. The lipid
residue was transesterified with 5% sulfuric acid in methanol, and
the methyl fatty acids were extracted into heptane. Separation was
achieved by injection into an SGE BPX-70 capillary column in a
Unicam series 610 gas chromatograph with temperature program-
ming. Data were collected with a Phillips PU6030 data capture
unit and processed using Unicam 4880 data handling software.
Fatty acid quantification was by internal standardization with
sample concentrations calculated by comparing the sample fatty
acid/internal standard ratio against the fatty acid/internal standard
ratio of known amounts of a commercial fatty acid standard within
a known linear range of standard ratios. The same amount of
internal standard was added to both standard and sample.
Table S1 Fatty acids added to a fat-deficient base diet
Values are expressed as the amount of fatty acid (in g) in 100 g of food (w/w). The control
diet is included for comparison purposes. A fourth supplemented diet was used consisting of
a fat-deficient base diet plus 1 % sunflower oil. None of the diets contained cholesterol and
were all isocaloric. MUFA, mono-unsaturated fatty acid; PUFA, polyunsaturated fatty acid; SFA,
saturated fatty acid. NA, not applicable.
Fatty acid Control diet SFA diet MUFA diet PUFA diet
Lauric acid (C12:0) 0.02 0.02 NA NA
Myristic acid (C14:0) 0.14 0.14 NA NA
Palmitic acid (C16:0) 0.31 0.31 NA NA
Stearic acid (C18:0) 0.04 0.04 NA NA
Myristoleic acid (C14:1) 0.02 NA 0.02 NA
Palmitoleic acid (C16:1) 0.09 NA 0.09 NA
Oleic acid (C18:1) 0.77 NA 0.77 NA
Linoleic acid (C18:2,n−6) 0.69 NA NA 0.69
Linolenic acid (C18:3,n−3) 0.06 NA NA 0.06
Arachidonic acid (C20:4,n − 6) 0.13 NA NA 0.13
Total fatty acids 2.27 0.51 0.88 0.88
Table S2 Fatty acid analysis of the diets used
Values are expressed as a percentage of total fatty acid content on a fresh weight basis. MUFA,
mono-unsaturated fatty acid; PUFA, polyunsaturated fatty acid; SFA, saturated fatty acid.
Control Sunflower
Fatty acid group diet SFA diet MUFA diet PUFA diet oil diet
Saturated fatty acids 19.3 96.5–97.9 1.9–3.4 29.2–30.2 12.4–13.3
Mono-unsaturated fatty acids 18.3 1.7–2.1 95.1–95.5 11.8 24.8–25.1
Polyunsaturated fatty acids 62.2 1.0–2.0 2.1–3.2 16.0–16.3 61.9–62.9
Other unknown fatty acids 0.2 0.9 1.29 41.7–43.0 0.9
Table S3 Fatty acid analysis of the diets used
Values are expressed on a w/w basis in the diet. MUFA, mono-unsaturated fatty acid; PUFA,
polyunsaturated fatty acid; SFA, saturated fatty acid.
Sunflower
Fatty acid group Control diet SFA diet MUFA diet PUFA diet oil diet
Lauric acid (C12:0) <0.003 0.016 0.001 0.004 0.001
Myristic acid (C14:0) 0.006 0.099 0.002 0.012 0.003
Myristoleic acid (C14:1,n − 5) <0.003 <0.001 0.012 0.003 <0.001
Pentadecanoic acid (C15:0) 0.003 0.001 0.001 0.1 0.001
Palmitic acid (C16:0) 0.48 0.32 0.009 0.05 0.067
Palmitoleic acid (C16:1,n − 7) 0.01 <0.001 0.07 0.003 0.001
Stearic acid (C18:0) 0.05 0.05 0.001 0.017 0.039
Oleic acid (C18:1,n − 9) 0.47 0.007 0.74 0.039 0.237
Vaccenic acid (C18:1,n − 7) 0.03 <0.001 0.01 0.002 0.006
Linoleic acid (C18:2,n − 6) 1.63 0.002 0.017 0.106 0.616
Linolenic acid (C18:3,n − 3) 0.17 <0.001 <0.001 0.002 0.001
Eicosanoic acid (C20:0) 0.01 <0.001 0.001 0.001 0.002
Gondoic acid (C20:1,n − 9) 0.02 <0.001 <0.001 0.004 0.002
Eicosadienoic acid 0.003 <0.001 <0.001 0.001 <0.001
(C20:2,n − 6)
Dihomo-γ -linolenic acid <0.003 <0.001 <0.001 <0.001 <0.001
(C20:3,n − 6)
Eicosatrienoic acid <0.003 0.001 0.001 0.008 0.001
(C20:3,n − 3)
Arachidonic acid (C20:4,n − 6) <0.003 <0.001 <0.001 0.001 <0.001
Eicosatetraenoic acid <0.003 <0.001 <0.001 0.001 <0.001
(C20:4,n−3)
Timnodonic acid (C20:5,n − 3) <0.003 <0.001 <0.001 0.002 0.001
Behenic acid (C22:0) 0.01 <0.001 <0.001 0.01 0.007
Cetoleic acid (C22:1,n − 11) 0.003 <0.001 <0.001 0.023 0.002
Erucic acid (C22:1,n − 9) 0.003 <0.001 <0.001 0.024 <0.001
Adrenic acid (C22:4,n − 6) 0.003 0.001 0.001 0.004 0.001
Osbond acid (C22:5,n − 6) 0.003 <0.001 <0.001 0.002 <0.001
Clupanodonic acid <0.003 <0.001 <0.001 0.003 <0.001
(C22:5,n − 3)
Docosahexaenoic acid <0.003 <0.001 <0.001 0.012 <0.001
(C22:6,n − 3)
Lignoceric acid (C24:0) 0.01 <0.001 <0.001 0.005 0.002
Nervonic acid (C24:1,n − 9) 0.003 <0.001 <0.001 0.007 <0.001
Unknown C4−10 acids <0.003 0.002 0.003 0.11 0.001
Unknown C10−15 acids <0.003 0.002 0.002 0.041 0.001
Unknown C15−20 acids 0.003 0.001 0.006 0.072 0.004
Unknown C20−25 acids 0.01 <0.001 0.001 0.157 0.003
1 To whom correspondence should be addressed (email c.r.wolf@dundee.ac.uk).
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Table S4 Fatty acid analysis of total hepatic lipids of control (Porlox /lox )
and HRN mice
Results are means +− S.E.M. (n = 3 livers). Fold change is expressed as the ratio of HRN mice
to control mice.
Fatty acid concentration (μM)
Fatty acid Control HRN P Fold change
Myristic acid (C14:0) 1.3 +− 0.2 3.5 +− 1.4 0.202 2.7
Palmitic acid (C16:0) 24.5 +− 1.0 86.7 +− 2.9 <0.001 3.5
Palmitoleic acid (C16:1) 2.5 +− 0.01 17.1 +− 3.8 0.019 6.8
Stearic acid (C18:0) 10.3 +− 0.2 25.2 +− 2.6 0.005 2.5
Oleic acid (C18:1) 15.2 +− 0.5 213.3 +− 18.1 <0.001 14.1
Linoleic acid (C18:2) 12.8 +− 0.5 38.8 +− 10.1 0.063 3.0
Eicosatrienoic acid (C20:3) 1.2 +− 0.1 7.5 +− 0.4 <0.001 6.2
Arachidonic acid (C20:4) 10.1 +− 0.6 18.3 +− 1.1 0.003 1.8
Docosahexaenoic acid (C22:6) 4.9 +− 0.2 11.1 +− 0.8 0.002 2.3
Table S5 Fatty acid analysis of total hepatic lipids of control (Porlox /lox )
and HRN mice
Results are means +− S.E.M. (n = 3 livers). Fold change is expressed as the ratio of HRN mice
to control mice.
Fatty acid concentration (μM)
Fatty acid group Control HRN P Fold change
Total 82.7 +− 1.1 421.4 +− 32.4 <0.001 5.1
C16:0/C18:0 ratio 2.4 +− 0.1 3.5 +− 0.3 0.024 1.5
Saturated 36.1 +− 1.1 115.4 +− 5.7 <0.001 3.2
Mono-unsaturated 17.7 +− 0.5 230.4 +− 20.8 <0.001 13.0
Polyunsaturated 28.9 +− 0.6 75.7 +− 11.9 0.018 2.6
n − 3 4.9 +− 0.2 11.1 +− 0.8 0.002 2.3
n − 6 24.1 +− 0.5 64.6 +− 11.2 0.022 2.7
Triacylglycerol (mM) 0.03 +− 0.0004 0.14 +− 0.01 <0.001 5.1
Table S6 The induction of other phenotypes in HRN mice on nuclear
receptor-null backgrounds
Pxr−/−/HRN, Car−/−/HRN and Pxr−/−/Car−/−/HRN mice were generated as outlined in the
Experimental section of the main text and were analysed at 12 weeks of age for non-fasting
plasma lipid concentrations and liver/body weight ratio as detailed in the Experimental section
of the main text. Results are means +− S.E.M. (n = 3). *P  0.05; **P  0.01; ***P  0.001
compared with Porlox /lox (control) mice. †P  0.05 compared with HRN mice.
Genotype Plasma cholesterol Plasma triacylglycerols Liver/body weight ratio
Control (Por lox /lox ) 3.73 +− 0.24 1.09 +− 0.27 0.051 +− 0.002
HRN 1.15 +− 0.10*** 0.29 +− 0.09* 0.075 +− 0.004**
Pxr−/− 2.31 +− 0.16* 0.41 +− 0.13 0.062 +− 0.001*
Car−/− 2.90 +− 0.05 0.70 +− 0.16 0.045 +− 0.002
Pxr−/−/Car−/− 2.60 +− 0.49 0.95 +− 0.01 0.051 +− 0.002
Pxr−/−/HRN 1.03 +− 0.32** 0.14 +− 0.01* 0.091 +− 0.002***
Car−/−/HRN 1.35 +− 0.15** 0.28 +− 0.04* 0.073 +− 0.007*
Pxr−/−/Car−/−/HRN 2.63 +− 0.28† 0.61 +− 0.12 0.073 +− 0.004**
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CAR-dependent fatty acid regulation of cytochromes P450
Figure S1 Relationship of CYP2B10 and CYP3A11 expression with loss of POR activity and hepatic lipid accumulation
Porlox /lox /CreCYP1A1 and Porlox /lox mice were treated with a single dose of 3MC (40 mg/kg of body weight), and harvested over a 28 day period. Hepatic triacylglycerol levels, mRNA
and protein levels of CYP2B10 and CYP3A11, and POR activity were determined as detailed in the Experimental section of the main text. (A) Relationship between POR activity and
(i) CYP2B10 protein, (ii) Cyp2b10 mRNA content. Correlation of Cyp2b10 mRNA with (iii) CYP2B10 protein and (iv) hepatic triacylglycerol (triglyceride) concentration. (B) Relationship
between POR activity and (i) CYP3A11 protein and (ii) Cyp3a11 mRNA content. Correlation of Cyp3a11 mRNA with (iii) CYP3A11 protein and (iv) hepatic triacylglycerol concentration. mRNA
expression and POR activity are expressed compared with 3MC-treated Porlox /lox mice. Results are means for three animals per experimental time point.
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Figure S2 Gene expression changes on loss of POR
Porlox /lox /CreCYP1A1 and Porlox/lox mice treated with a single dose of 3MC (40 mg/kg of body
weight) were analysed for changes in the expression levels of various genes involved in
controlling hepatic lipid levels. mRNA expression of the fatty-acid transporter CD36 (A), FAS
(B), CPT1a (C) and CAR (D) as a function of time post 3MC administration. Results are
means +− S.E.M. (n = 3) and are expressed as a fold change compared with Porlox/lox mice at
the same time point. *P  0.05.
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Figure S3 Development of phenotypic changes in conditional HRN mice on
restricted fatty acid diets
Porlox /lox /CreCYP1A1 and Porlox /lox mice were maintained on a control, fat-deficient or
fatty-acid-supplemented diet until 12 weeks of age as outlined in the Experimental section
of the main text, then treated with a single dose of 3MC (40 mg/kg of body weight) and
killed 14 days later. Plasma lipid concentrations and liver/body weight ratios were determined as
detailed in the Experimental section of the main text. (A) Non-fasting total plasma cholesterol. (B)
Non-fasting plasma triacylglycerol (triglyceride) levels. (C) Liver/body weight ratio. Black bars:
Por lox /lox /CreCYP1A1. Grey bars: Por lox /lox . Results are means +− S.E.M. (n = 3). *P  0.05;
**P  0.01 compared with the same experimental conditions for Porlox /lox mice. aP  0.05;
bP  0.01 compared with mice of the same genotype on a control diet. SFA, saturated fatty acids;
MUFA, mono-unsaturated fatty acids; PUFA, polyunsaturated fatty acids; SunFl, 1 % sunflower
oil.
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